PSC Biotech: FDA Form 483 Throughput Up 10x, Processing Costs Down 44%

PSC Biotech is a global life-sciences consultancy founded in 1996. It helps HCLS companies in 52 countries develop, manufacture, and distribute healthcare products to the regulatory bar. Thousands of FDA Form 483 observations pass through PSC Biotech every year.

01 The Challenge

Manual review of FDA Form 483 observations was the tax on every compliance engagement

Most of the document work at PSC Biotech was manual. Throughput depended entirely on headcount. Accuracy fluctuated with reviewer attention. Processing costs climbed as volume climbed.

The stakes are not abstract: an FDA Form 483 observation flags a potential regulatory violation. Missing the required response window can cost an HCLS company millions or billions in fines. A mistake by a document reviewer can ripple through the health of millions of people.

PSC Biotech handles thousands of 483s per year. The pipeline needed to scale without proportional headcount — and without dropping the quality that the FDA process demands.

02 The Approach

Ship a classifier that clears a measured precision and recall bar, then build the infrastructure around it

Provectus opened with data preparation and environment setup, then built a baseline text-classification model. Several transformer-based encoder architectures (including BERT) and NLP approaches were evaluated against the PSC Biotech data. The final model is a multi-label classifier that categorizes observations into 100+ labels while maintaining 70%+ precision and recall — the quality gate the engagement required before production.

With the gate cleared, the team moved to operationalization: a service layer for model usage, deployment and update workflows, continuous-improvement feedback loops, and the production-grade infrastructure to run them.

03 The Build

Bedrock-integrated classifier, a reviewer UI, and a CI/CD loop that retrains on real data

The classifier is integrated with Amazon Bedrock for foundation-model substitutability. Today PSC Biotech runs on the model that cleared the engagement’s precision and recall gate. Tomorrow, new foundation models can be swapped in without rewriting the pipeline — with room to push precision and recall toward 95%.

Document mappers and reviewers get a UI that surfaces the model’s classification alongside the original observation, lets them confirm or correct the label, and exports into the existing PSC Biotech document-processing pipeline. The CI/CD loop retrains the model and promotes a new version when it clears the benchmark on fresh data.

04 The Results

10x throughput, 44% lower per-document cost, 5,000 hours back per year

10x

Regulatory-compliance document throughput

Measured against the manual baseline

Document-centric operations accelerated 90%. Processing cost per document dropped 44%. The firm saved 5,000 hours of mapper and reviewer time per year. Estimated return on investment over the first twelve months was 93%.

The improvements compound: faster 483 turnaround means PSC Biotech clients respond to FDA observations inside the required window more reliably, with less firefighting.

05 What’s Next

The same shape applies to every document-heavy compliance workload PSC Biotech runs

The classifier plus UI plus CI/CD loop is a reusable shape inside PSC Biotech’s document operations. Additional compliance workloads — not just 483s — can adopt the same pattern with a new target taxonomy and re-tuned model. Provectus and PSC Biotech continue the engagement against that extension path.